IP Library Granted Patent US 7,067,533
Granted Patent B2
US 7,067,533 · App. 10/009,566 · Granted Jun 27, 2006

Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,533
App. No.
10/009,566
Granted
Jun 27, 2006
Kind
B2
Abstract

The present invention relates to an aminophenoxyacetamide derivative of the formula (I): wherein R 1 to R 4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E 1 is —NR 4 —; and E 2 is an oxygen atom or —NR 10 —; Q is the group —X—Y-Q′, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and Y is selected from a group comprising C═O, NHC(═), and C(═O)NH, and Q′ is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.

Claims (29)

1. An aminophenoxyacetamide derivative represented by the following formula (I):

wherein:

R 1 , R 2 , R 3 and R 4 are, independent from each other, hydrogen atom or lower alkyl group;

R 5 R 6 R 7 and R 8 are, independent from each other, hydrogen atom or lower alkyl group;

E 1 is group —NR 9 — (in which, R 9 is hydrogen atom or lower alkyl group);

E 2 is oxygen atom or group —NR 10 — (in which, R 10 is hydrogen atom or lower alkyl group which may be substituted);

Q is a group of —X—Y-Q′, wherein X is a connecting bond, lower alkyl group, lower alkenyl group, or lower alkenyl group; Y is a connecting bond, or a group selected from the groups consisting of C═O, C(═O)NH, NHC(═O), —O—, —S—, CH(OH), —O—CH(OH)— and —O—CH 2 —CH(OH)—, in which hydrogen atom of amido group may be substituted with lower alkyl group; and Q′ is hydrogen atom or a cyclic group selected from the group consisting of phenyl group, pyridily group, quinolyl group, isoquinolyl group, benzothiazole group, benzimidazole group, morpholinyl group, and cyclic hydrocarbon group, wherein one or more of the hydrogen atoms in the cyclic group of Q′ may be substituted;

either in the case that E 2 is the group —NR 10 — then X and Y are both connecting bond and Q′ is not hydrogen atom; or in the case that E 2 is the group —O— then all of the groups R 1 , R 2 , R 3 and R 4 are methyl group; or a pharmaceutically acceptable salt thereof.

2. The aminophenoxyacetamide derivative of formula (I) claimed in claim 1 , wherein X and Y are both connecting bond; or pharmaceutically acceptable salts thereof.

3. The aminophenoxyacetamide derivative of formula (I) claimed in claim 1 , wherein one of X and Y is other than connecting bond and E 2 is the group —O— and all of the groups of R 1 , R 2 , R 3 and R 4 are other than hydrogen atom, wherein X, Y, R 1 , R 2 , R 3 and R 4 are the same as defined above in claim 1 ; or pharmaceutically acceptable salts thereof.

4. A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 1 as an active ingredient.

5. A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 2 as an active ingredient.

6. A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 3 as an active ingredient.

7. An aminophenoxyacetamide derivative represented by the following formula (I):

wherein:

R 1 , R 2 , R 3 and R 4 are, independent from each other, hydrogen atom or lower alkyl group;

R 5 R 6 R 7 and R 8 are, independent from each other, hydrogen atom or lower alkyl group;

E 1 is group —NR 9 — (in which, R 9 is hydrogen atom or lower alkyl group);

E 2 is oxygen atom or group —NR 10 — (in which, R 10 is hydrogen atom or lower alkyl group which may be substituted);

Q is a group of —X—Y-Q′, wherein X is a connecting bond, lower alkyl group, lower alkenyl group, or lower alkenyl group; Y is a connecting bond, or a group selected from the groups consisting of C═O, C(═O)NH, NHC(═O), —O—, —S—, CH(OH), —O—CH(OH)— and —O—CH 2 —CH(OH)—, in which hydrogen atom of amido group may be substituted with lower alkyl group; and Q′ is hydrogen atom or a cyclic group selected from the group consisting of phenyl group, pyridily group, ciuinolyl group, isociuinolyl group, benzothiazole group, benzimidazole group, morpholinyl group, and cyclic hydrocarbon group, wherein one or more of the hydrogen atoms in the cyclic group of Q′ may be substituted;

either in the case that E 2 is the group —NR— then X and Y are both connecting bond and Q′ is not hydrogen atom; or in the case that E 2 is the group —O— then all of the groups R 1 , R 2 , R 3 and R 4 are methyl group; or a pharmaceutically acceptable salt thereof,

where Q′ is a cyclic hydrocarbon group and said cyclic hydrocarbon group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

8. An aminophenoxyacetamide derivative represented by the following formula (I):

wherein:

R 1 , R 2 , R 3 and R 4 are, independent from each other, hydrogen atom or lower alkyl group;

R 5 R 6 R 7 and R 8 are, independent from each other, hydrogen atom or lower alkyl group;

E 1 is group —NR 9 — (in which, R 9 is hydrogen atom or lower alkyl group); E 2 is oxygen atom or group —NR 10 — (in which, R 10 is hydrogen atom or lower alkyl group which may be substituted);

Q is a group of —X—Y-Q′, wherein X is a connecting bond, lower alkyl group, lower alkenyl group, or lower alkenyl group; Y is a connecting bond, or a group selected from the groups consisting of C═O, C(═O)NH, NHC(═O), —O—, —S—, CH(OH), —O—CH(OH)— and —O—CH 2 —CH(OH)—, in which hydrogen atom of amido group may be substituted with lower alkyl group; and Q′ is hydrogen atom or a cyclic group selected from the group consisting of phenyl group, pyridily group, ciuinolyl group, isociuinolyl group, benzothiazole group, benzimidazole group, morpholinyl group, and cyclic hydrocarbon group, wherein one or more of the hydrogen atoms in the cyclic group of Q′ may be substituted;

either in the case that E 2 is the group —NR 10 — then X and Y are both connecting bond and Q′ is not hydrogen atom; or in the case that E 2 is the group —O— then all of the groups R 1 R 2 , R 3 and R 4 are methyl group; or a pharmaceutically acceptable salt thereof, wherein Q′ is an unsaturated or saturated heterocyclic group and said unsaturated or saturated heterocyclic group is morpholinyl.

Assignments (4)
CHANGE OF NAME Recorded May 29, 2007
From: DAIICHI ASUBIO PHARMA CO., LTD.
To: ASUBIO PHARMA CO., LTD.
Reel/Frame 019341/0642 →
CHANGE OF NAME Recorded Dec 21, 2005
From: DAIICHI SUNTORY PHARMA CO., LTD.
To: DAIICHI ASUBIO PHARMA CO., LTD.
Reel/Frame 017384/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2003
From: SUNTORY LIMITED
To: DAIICHI SUNTORY PHARMA CO., LTD.
Reel/Frame 013865/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2001
From: TAKEMOTO, NAOHIRO; ANNOURA, HIROKAZU; MURAYAMA, NORIHITO
To: SUNTORY LIMITED
Reel/Frame 012595/0432 →